reports
Landstar to Participate in Bank of America 2024 Annual Investment Conf...
Landstar to Participate in Bank of America 2024 Annual Investment Conference JACKSONVILLE, Fla., May 07, 2024 (GLOBE NEWSWIRE) -- Landstar System, Inc. (NASDAQ:LSTR) announced today its participation in the Bank of America 2024 Annual Investment Conference. Landstar’s “fireside chat” discussion begins at 10:20 a.m. ET on Tuesday, May 14. It will be broadcast live via the Internet at ; click on "Webcasts." The Bank of America 2024 Annual Investment Conference webcast will be available on Landstar’s website through May 22. For more information about the webcast, please contact Landstar’s In...
Form 8.3 - Balanced Commercial Property Trust Limited
Form 8.3 - Balanced Commercial Property Trust Limited 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser:Rathbones Group Plc(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. (c) Name of offeror/offeree in relation to whose relevant se...
Raffles Medical Group Ltd: 1 director
A director at Raffles Medical Group Ltd bought 500,000 shares at 1.000SGD and the significance rating of the trade was 56/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two y...
Hunan Coran New Energy Co Ltd: 3 directors
Three Directors at Hunan Coran New Energy Co Ltd bought 63,600 shares at between 4.246CNY and 4.280CNY. The significance rating of the trade was 57/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's dir...
Form 8.3 - Alpha Financial Markets Consulting Plc
Form 8.3 - Alpha Financial Markets Consulting Plc 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser:Rathbones Group Plc(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. (c) Name of offeror/offeree in relation to whose relevant securi...
Clearmind Medicine Secures Exclusive Global Rights to Breakthrough Psy...
Clearmind Medicine Secures Exclusive Global Rights to Breakthrough Psychedelic Compounds for PTSD Treatment Vancouver, Canada, May 07, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announces the signing of an exclusive patent licensing agreement with Yissum Research Development Company of the Hebrew University of Jerusalem. This agreement provides Clearmind with exclusiv...
Form 8.3 - Abrdn European Logistics Income Plc
Form 8.3 - Abrdn European Logistics Income Plc 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser:Rathbones Group Plc(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. (c) Name of offeror/offeree in relation to whose relevant securitie...
Tompkins Financial Corp: 1 director
A director at Tompkins Financial Corp sold 4,099 shares at 0.000USD and the significance rating of the trade was 57/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years c...
Reneo Pharmaceuticals Reports First Quarter 2024 Financial Results
Reneo Pharmaceuticals Reports First Quarter 2024 Financial Results IRVINE, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a pharmaceutical company historically focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today reported financial results for the first quarter ended March 31, 2024. First Quarter and Recent Highlights In December 2023, the pivotal STRIDE study of mavodelpar in adult patients with primary mitochondrial myopathies did not meet its primary efficacy or sec...
Caledonia Mining Corporation Plc: Results of Annual General Meeting
Caledonia Mining Corporation Plc: Results of Annual General Meeting ST HELIER, Jersey, May 07, 2024 (GLOBE NEWSWIRE) -- Caledonia Mining Corporation Plc ("the Company") (NYSE American, AIM and VFEX: CMCL) announces the results of its annual general meeting of shareholders (the “AGM”) held at St Helier, Jersey today. The total number of shareholders present in person or by proxy at the AGM was 96, representing 62.28% of the Company’s outstanding voting shares. The table below shows the proxy votes received on resolutions 1(a) to 1(h), which were duly passed by a show of hands, to rea...
Crown Castle’s Highly Qualified Board of Directors is Driving Strategi...
Crown Castle’s Highly Qualified Board of Directors is Driving Strategic Actions to Enhance Value Refreshed Board Has Deep Expertise in Telecom, Towers and Fiber Industries as well as C-Suite and Investment Professional Experience Boots Capital Nominees Lack Additive Skills Crown Castle Urges Shareholders to Vote “FOR” ONLY Crown Castle’s 12 Director Nominees on the WHITE Proxy Card or Voting Instruction Form HOUSTON, May 07, 2024 (GLOBE NEWSWIRE) -- Crown Castle Inc. (NYSE: CCI) (“Crown Castle” or the “Company”) today sent a letter to shareholders in connection with its upcoming 2024 ...
Chin Hin Group Berhad: 1 director
A director at Chin Hin Group Berhad bought 1,000,000 shares at 2.700MYR and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two yea...
Neuronetics Reports Record First Quarter 2024 Financial and Operating ...
Neuronetics Reports Record First Quarter 2024 Financial and Operating Results MALVERN, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “Neuronetics”) a commercial stage medical technology company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the best neurohealth therapies in the world, today announced its financial and operating results for the first quarter of 2024. First Quarter 2024 Highlights First quarter 2024 revenue of $17.4 million, a 12% increase as compared to the first qua...
Altimmune to Participate at Two Upcoming Investor Conferences
Altimmune to Participate at Two Upcoming Investor Conferences GAITHERSBURG, Md., May 07, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate and be available for 1x1 meetings at the following investor conferences: JMP Life Sciences Conference (New York, NY)Tuesday, May 14, 2024Fireside Chat at 9:00 a.m. Eastern Time UBS Obesity Therapeutics Day (Virtual Conference)Thursday, May 23, 2024Fireside Chat at 10:00 a.m. Eastern Time The sessions will be webcast and can be accessed b...
Hillman Reports First Quarter 2024 Results
Hillman Reports First Quarter 2024 Results CINCINNATI, May 07, 2024 (GLOBE NEWSWIRE) -- () (the “Company” or “Hillman”), a leading provider of hardware products and merchandising solutions, reported financial results for the thirteen weeks ended March 30, 2024. First Quarter 2024 Highlights (Thirteen weeks ended March 30, 2024) Net sales increased 0.2% to $350.3 million compared to $349.7 million in the prior year quarterNet loss totaled $(1.5) million, or $(0.01) per diluted share, compared to net loss of $(9.1) million, or $(0.05) per diluted share, in the prior year quarterAdjusted ...
Invivyd to Pursue Rapid Immunobridging Pathway to Potential EUA for Tr...
Invivyd to Pursue Rapid Immunobridging Pathway to Potential EUA for Treatment of COVID-19 in Moderately to Severely Immunocompromised People, Based on U.S. FDA Feedback Pathway leverages immunobridging approach via serum virus neutralizing antibody (sVNA) titers enabled by prior successful COVID-19 treatment clinical trial “STAMP” conducted with prototype antibody adintrevimabCompany anticipates submitting a COVID-19 treatment EUA application for PEMGARDA™ (pemivibart) imminentlyCOVID-19 treatment EUA pathway offers a novel, rapid pathway to potential second EUA for pemivibartInvivyd leaves...
Dave Reports Record First Quarter 2024 Results
Dave Reports Record First Quarter 2024 Results Record Q1 Revenue of $73.6 Million; Y/Y Revenue Growth Accelerates for Second Consecutive Quarter Q1 GAAP Net Income Reaches $34.2 Million and Adj. EBITDA Increases to $13.2 Million Dave Raises 2024 Adjusted EBITDA Guidance to $30-$40 Million LOS ANGELES, May 07, 2024 (GLOBE NEWSWIRE) -- Dave Inc. (“Dave” or the “Company”) (Nasdaq: DAVE), one of the nation’s leading neobanks, today reported its financial results for the first quarter ended March 31, 2024. “2024 is off to a strong start as we exceeded growth and profitability expectations ...
Amesite Announces Strategic Five-Year Partnership with Franciscan Miss...
Amesite Announces Strategic Five-Year Partnership with Franciscan Missionaries of Our Lady University to Deliver Healthcare Training for Healthcare Professionals Franciscan Missionaries of Our Lady University is Sixth Contract Win Since Introducing No Setup-fee Plan DETROIT, May 07, 2024 (GLOBE NEWSWIRE) -- Amesite Inc. (NASDAQ: AMST), a leading artificial intelligence software company offering a cloud-based learning platform for business and education markets, announces a five-year (5) partnership with Franciscan Missionaries of Our Lady University to deliver healthcare training progra...
Knight to Present at the 2024 RBC Capital Markets Global Healthcare Co...
Knight to Present at the 2024 RBC Capital Markets Global Healthcare Conference in New York City MONTREAL, May 07, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a leading pan-American (ex-US) specialty pharmaceutical company, announced today that Samira Sakhia, President and Chief Executive Officer, is scheduled to participate in a fireside chat at the 2024 RBC Capital Markets Global Healthcare Conference on Tuesday, May 14, 2024 at 3:05 pm ET at the InterContinental New York Barclay hotel in New York City. About Knight Therapeutics Inc. Knight Therapeutics In...
Knight présentera à la conférence sur la santé internationale de 2024 ...
Knight présentera à la conférence sur la santé internationale de 2024 de RBC Marchés des Capitaux à New York MONTRÉAL, 07 mai 2024 (GLOBE NEWSWIRE) -- Thérapeutique Knight inc. (TSX : GUD) (« Knight »), société pharmaceutique spécialisée panaméricaine (ex-ÉU) et chef de file, a annoncé aujourd'hui que Samira Sakhia, présidente et chef de la direction, participera à une discussion lors de la conférence sur la santé internationale de 2024 de RBC Marchés des Capitaux, mardi 14 mai 2024 à 15 h 05 (HE) à l'hôtel InterContinental New York Barclay à New York. À propos de Thérapeutique Knight in...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.